Abstract:Aims/hypothesis The use of oral glucose-lowering drugs, particularly those designed to target the gut ecosystem, is often observed in association with altered gut microbial composition or functional capacity in individuals with type 2 diabetes. The gut microbiota, in turn, plays crucial roles in the modulation of drug efficacy. We aimed to assess the impacts of acarbose and vildagliptin on human gut microbiota and the relationships between pre-treatment gut microbiota and therapeutic responses. Methods This was a randomised, open-labelled, two-arm trial in treatment-naive type 2 diabetes patients conducted in Beijing between December 2016 and December 2017. One hundred participants with overweight/obesity and newly diagnosed type 2 diabetes were recruited from the Pinggu Hospital and randomly assigned to the acarbose ( n =50) or vildagliptin ( n =50) group using sealed envelopes. The treatment period was 6 months. Blood, faecal samples and visceral fat data from computed tomography images were collected before and after treatments to measure therapeutic outcomes and gut microbiota. Metagenomic datasets from a previous type 2 diabetes cohort receiving acarbose or glipizide for 3 months were downloaded and processed. Statistical analyses were applied to identify the treatment-related changes in clinical variables, gut microbiota and associations. Results Ninety-two participants were analysed. After 6 months of acarbose ( n =44) or vildagliptin ( n =48) monotherapy, both groups achieved significant reductions in HbA 1c (from 60 to 46 mmol/mol [from 7.65% to 6.40%] in the acarbose group and from 59 to 44 mmol/mol [from 7.55% to 6.20%] in the vildagliptin group) and visceral fat areas (all adjusted p values for pre–post comparisons <0.05). Both arms showed drug-specific and shared changes in relative abundances of multiple gut microbial species and pathways, especially the common reductions in Bacteroidetes species. Three months and 6 months of acarbose-induced changes in microbial composition were highly similar in type 2 diabetes patients from the two independent studies. Vildagliptin treatment significantly enhanced fasting active glucagon-like peptide-1 (GLP-1) levels. Baseline gut microbiota, rather than baseline GLP-1 levels, were strongly associated with GLP-1 response to vildagliptin, and to a lesser extent with GLP-1 response to acarbose. Conclusions/interpretation This study reveals common microbial responses in type 2 diabetes patients treated with two glucose-lowering drugs targeting the gut differently and acceptable performance of baseline gut microbiota in classifying individuals with different GLP-1 responses to vildagliptin. Our findings highlight bidirectional interactions between gut microbiota and glucose-lowering drugs. Trial registration ClinicalTrials.gov NCT02999841 Funding National Key Research and Development Project: 2016YFC1304901. Graphical abstract

Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study.

Efficacy and Safety of Combination Therapy with Vildagliptin and Metformin Versus Metformin Uptitration in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Randomized, Open-Label, Prospective Study (Vision)

Efficacy and Safety of Combination Therapy with Vildagliptin and Metformin Versus Metformin Up-Titration in Chinese Patients with Type 2 Diabetes Mellitus: Study Design and Rationale of the Vision Study

Efficacy and Safety of Vildagliptin and Metformin Combination Therapy in Type 2 Diabetes

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients with Type 2 Diabetes and Coronary Artery Disease

Associations of Triglycerides/High-Density Lipoprotein Cholesterol Ratio With Insulin Resistance, Impaired Glucose Tolerance, and Diabetes in American Adults at Different Vitamin D3 Levels

Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.

Treatment With Metformin And A Dipeptidyl Peptidase-4 Inhibitor Elevates Apelin Levels In Patients With Type 2 Diabetes Mellitus

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study

Machine learning assessment of vildagliptin and linagliptin effectiveness in type 2 diabetes: Predictors of glycemic control

Metagenomic Analysis Reveals Crosstalk Between Gut Microbiota and Glucose-Lowering Drugs Targeting the Gastrointestinal Tract in Chinese Patients with Type 2 Diabetes: a 6 Month, Two-Arm Randomised Trial.

Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes

Therapeutics 483 Vildagliptin add-on to metformin versus metformin uptitration in Chinese patients with type 2 diabetes : A sub-group analysis of the VISION study

Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA

Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease

Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus

Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study

Impact of Baseline and Trajectory of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management